Bristol-Myers Squibb seeks further immuno-oncology patent revenues with AstraZeneca suit
The company has already secured lucrative settlements with Merck and Roche
The company has already secured lucrative settlements with Merck and Roche
Director General José Sánchez Pérez meets with local lawyers to discuss enforcement and implementation of IP law
A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs
08 March 2022
Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator
07 March 2022
As the US and European gene-editing IP landscapes drift further apart, therapeutics companies face difficult freedom-to-operate quandaries
03 March 2022
Some of the highest-value deals in intellectual property today are taking place in the burgeoning marketplace for revenue streams linked to pharmaceutical products
02 March 2022
Study reveals the significance of manufacturing IP rights in BPCIA litigation
25 February 2022
Dispute resolution teams will want to steer clear of the sunshine state following a recent federal court decision
24 February 2022
In a closely watched case, the Supreme Court has upheld the Civil Code’s prioritising of people’s lives and health during the covid-19 pandemic, over profits lost to patent owners
23 February 2022
Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents
22 February 2022
The German biotech company becomes the second mRNA vaccine maker to say it will not take legal action during pandemic
21 February 2022
Five takeaways from a Federal Circuit majority decision declining to rehear en banc a skinny label dispute between GSK and Teva
17 February 2022
Unlock unlimited access to all IAM content